Preclinical incorporation Dosimetry of [F-18]FACH a novel 18F-labeled MCT1/MCT4 lactate transport inhibitor

Conclusions: The ED upon i.v. application of about 300 MBq [F-18]FACH to humans would be 6.5 mSv, taking into account that preclinical dosimetry underestimates the dose to humans by up to 40% [3]. This is well within the range of what other F-18-labeled PET tracers cause to humans. This risk assessment encourages to transfer [F-18]FACH to clinical study phases to further investigate it’s potential as a clinical tool for cancer imaging with PET. References: [1] Halestrap, AP. Mol Aspects Med 2013, 34, 337-349. [2] Pinheiro, C et al. J Bioenerg Biomembr 2012, 44, 127-139. [3] Sattler, B et al. J Nucl Med 2014, 55, 1885-1892.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Sattler, B., Kranz, M., Sadeghzadeh, M., Wenzel, B., Moldovan, R.-P., Toussaint, M., Deuther-Conrad, W., Fischer, S., Ludwig, F.-A., Teodoro, R., Gurrapu, S., Drewes, L., Sabri, O., Brust, P. Tags: Dosimetry Posters Source Type: research